209 related articles for article (PubMed ID: 23295939)
1. The impact of geographic variations in treatment on outcomes in ovarian cancer.
Dehaeck U; McGahan CE; Santos JL; Carey MS; Swenerton KD; Kwon JS
Int J Gynecol Cancer; 2013 Feb; 23(2):282-7. PubMed ID: 23295939
[TBL] [Abstract][Full Text] [Related]
2. The significance of combination chemotherapy in epithelial ovarian cancer.
Kwon JS; McGahan C; Dehaeck U; Santos J; Swenerton K; Carey MS
Int J Gynecol Cancer; 2014 Feb; 24(2):226-32. PubMed ID: 24401982
[TBL] [Abstract][Full Text] [Related]
3. [Re-evaluation of interval debulking surgery in advanced epithelial ovarian cancer].
Ma Y; Li Y; Cui H; Liang XD; Tang ZJ; Li XP; Zhao Y; Wei LH
Zhonghua Fu Chan Ke Za Zhi; 2012 May; 47(5):355-60. PubMed ID: 22883524
[TBL] [Abstract][Full Text] [Related]
4. Reporting 'Denominator' data is essential for benchmarking and quality standards in ovarian cancer.
Phillips A; Balega J; Nevin J; Singh K; Elattar A; Kehoe S; Sundar S
Gynecol Oncol; 2017 Jul; 146(1):94-100. PubMed ID: 28411948
[TBL] [Abstract][Full Text] [Related]
5. Clinical characteristics and outcomes of patients with stage I epithelial ovarian cancer compared with fallopian tube cancer.
Rauh-Hain JA; Foley OW; Winograd D; Andrade C; Clark RM; Vargas RJ; Hinchcliff EM; Esselen KM; Horowitz NS; del Carmen MG
Am J Obstet Gynecol; 2015 May; 212(5):600.e1-8. PubMed ID: 25514761
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of postoperative morbidities in patients with advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy and delayed primary surgical debulking.
Le T; Alshaikh G; Hopkins L; Faught W; Fung MF
Ann Surg Oncol; 2006 Dec; 13(12):1711-6. PubMed ID: 17009146
[TBL] [Abstract][Full Text] [Related]
7. Trends in the receipt of guideline care and survival for women with ovarian cancer: A population-based study.
Warren JL; Harlan LC; Trimble EL; Stevens J; Grimes M; Cronin KA
Gynecol Oncol; 2017 Jun; 145(3):486-492. PubMed ID: 28372872
[TBL] [Abstract][Full Text] [Related]
8. Trends in therapy and survival of advanced stage epithelial ovarian cancer patients in the Netherlands.
van Altena AM; Karim-Kos HE; de Vries E; Kruitwagen RF; Massuger LF; Kiemeney LA
Gynecol Oncol; 2012 Jun; 125(3):649-54. PubMed ID: 22370602
[TBL] [Abstract][Full Text] [Related]
9. Histopathology predicts clinical outcome in advanced epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and debulking surgery.
Muraji M; Sudo T; Iwasaki S; Ueno S; Wakahashi S; Yamaguchi S; Fujiwara K; Nishimura R
Gynecol Oncol; 2013 Dec; 131(3):531-4. PubMed ID: 24096109
[TBL] [Abstract][Full Text] [Related]
10. Does neoadjuvant chemotherapy plus cytoreductive surgery improve survival rates in patients with advanced epithelial ovarian cancer compared with cytoreductive surgery alone?
Solmaz U; Mat E; Dereli ML; Turan V; Peker N; Tosun G; Dogan A; Adiyeke M; Ozdemir A; Gungorduk K; Sanci M; Yildirim Y
J BUON; 2015; 20(3):847-54. PubMed ID: 26214639
[TBL] [Abstract][Full Text] [Related]
11. Optimizing the treatment of ovarian cancer: Neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resection.
Gill SE; McGree ME; Weaver AL; Cliby WA; Langstraat CL
Gynecol Oncol; 2017 Feb; 144(2):266-273. PubMed ID: 27916269
[TBL] [Abstract][Full Text] [Related]
12. Primary surgery or neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer.
Vergote I; Amant F; Kristensen G; Ehlen T; Reed NS; Casado A
Eur J Cancer; 2011 Sep; 47 Suppl 3():S88-92. PubMed ID: 21944035
[TBL] [Abstract][Full Text] [Related]
13. [Treatment and prognostic factors for stage IV epithelial ovarian cancer].
Wu M; Shen K; Lang J
Zhonghua Fu Chan Ke Za Zhi; 2000 Apr; 35(4):200-3. PubMed ID: 11776158
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant intraarterial chemotherapy and embolization in treatment of advanced ovarian epithelial carcinoma.
Liu EL; Mi RR
Chin Med J (Engl); 2004 Oct; 117(10):1547-51. PubMed ID: 15498381
[TBL] [Abstract][Full Text] [Related]
15. The influence of neighborhood socioeconomic status and race on survival from ovarian cancer: a population-based analysis of Cook County, Illinois.
Brewer KC; Peterson CE; Davis FG; Hoskins K; Pauls H; Joslin CE
Ann Epidemiol; 2015 Aug; 25(8):556-63. PubMed ID: 25986734
[TBL] [Abstract][Full Text] [Related]
16. Appropriate Recommendations for Surgical Debulking in Stage IV Ovarian Cancer.
Chern JY; Curtin JP
Curr Treat Options Oncol; 2016 Jan; 17(1):1. PubMed ID: 26714493
[TBL] [Abstract][Full Text] [Related]
17. [Value of CA(125) in the prediction of optimal interval debulking surgery and its prognosis in patients with epithelial ovarian cancer].
Mu T; Li XP; Wang JL; Wang SJ; Wang Y; Sun XL; Cui H; Wei LH
Zhonghua Fu Chan Ke Za Zhi; 2012 Aug; 47(8):566-70. PubMed ID: 23141174
[TBL] [Abstract][Full Text] [Related]
18. Risk factors for septic adverse events and their impact on survival in advanced ovarian cancer patients treated with neoadjuvant chemotherapy and interval debulking surgery.
Son JH; Lee JH; Jung JA; Kong TW; Paek J; Chang SJ; Ryu HS
Gynecol Oncol; 2018 Oct; 151(1):32-38. PubMed ID: 30122310
[TBL] [Abstract][Full Text] [Related]
19. Associations between residual disease and survival in epithelial ovarian cancer by histologic type.
Melamed A; Manning-Geist B; Bregar AJ; Diver EJ; Goodman A; Del Carmen MG; Schorge JO; Rauh-Hain JA
Gynecol Oncol; 2017 Nov; 147(2):250-256. PubMed ID: 28822556
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of second-look laparotomy for surgically confirmed early-stage epithelial ovarian cancer: a multicenter retrospective study.
Sato N; Akahira J; Kitamura T; Aoki M; Yoshinaga K; Okamura C; Utsunomiya H; Shimizu T; Niikura H; Ito K; Okamura K; Yaegashi N
Int J Clin Oncol; 2003 Feb; 8(1):40-4. PubMed ID: 12601541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]